In the first part of the study, six volunteers received four doses of DS (0.5, 1, 1.5, and 2 mg/kg) in a vein of the opposite arm, with I week between injections and in random order. In the second part of the study, I 2 additional volunteers received 1.5 mg/kg of DS, by IV, IM, and SC route according to a randomized crossover administration. After DS injection, I 1 to I 3 citrated blood samples were obtained in 24 hours. These samples were centrifuged immediately (3,000 g for 1 5 mmutes at room temperature), and the platelet-poor plasmas were stored at -30#{176}C until assayed. These protocols were approved by the ethical committee of the Midi Pyr#{233}n#{233}es region. 
MATERIALS AND METHODS

DS
Assay of DS.
The method for measuring D5 in plasma was described in detail previously.7
In the present work, we adapted this method to the automate SBA 300 (Corning-Gilford, Oberlin, OH). The principle of the assay involves estimation of the residual amidolytic thrombin activity after a short incubation of thrombin with heparin cofactor II (HC II) in defibrinated plasma containing DS.
One volume of citrated platelet-poor plasma was mixed with 1 vol ofa 100 mg/mL Bentonite (Sigma, St Louis) suspension in Tris 0.02 mob/L (pH 7.4) buffer. After strong mixing, the tubes were centrifuged and the supernatant was placed in the sample cup ring of the automate. 
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